Contingency Management for Depression and Cannabis Use
(CLEAR Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to understand how using or stopping cannabis affects depression and suicidal thoughts in teenagers. The main focus is on contingency management, a behavioral therapy that encourages teens to stop using cannabis by offering rewards. The study includes participants who use cannabis almost daily and often feel depressed. Participants should have access to a smartphone and be willing to share their progress. As an unphased trial, this study offers a unique opportunity for teens to contribute to important research that could enhance mental health interventions.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators.
What prior data suggests that this contingency management protocol is safe for adolescents?
A previous study showed that contingency management (CM) helps people reduce or quit using cannabis, especially those with mental health issues like depression. This approach uses rewards to encourage abstinence from cannabis. Research shows it results in more negative drug tests, indicating reduced cannabis use.
Importantly, CM is considered safe and typically does not cause harmful side effects. The reviewed studies did not report significant negative effects linked to this treatment. Overall, CM appears to be a well-tolerated method for reducing cannabis use.12345Why are researchers excited about this trial?
Researchers are excited about the Contingency Management protocol for depression and cannabis use because it offers a unique approach to treatment by incentivizing cannabis abstinence. Unlike traditional treatments that might focus on therapy or medication to manage depression, this method uses an escalating remuneration system to encourage participants to stay away from cannabis. This approach not only targets cannabis use directly but also potentially enhances mood by promoting abstinence, which could lead to improved mental health outcomes. The biochemical confirmation of abstinence through decreasing THCCOOH levels adds a reliable measure to this innovative strategy.
What evidence suggests that contingency management for cannabis abstinence could be effective for depression and cannabis use?
Research has shown that contingency management (CM), which participants in this trial may receive, effectively helps people reduce or quit cannabis use. Studies have found that CM leads to more negative drug tests and less cannabis use, particularly in individuals with depression. CM uses rewards to encourage individuals to stop using cannabis and has successfully helped them quit. Evidence also suggests that CM can change how people think and act regarding cannabis use, even after the rewards end. This approach shows promise in helping people cut down or stop cannabis use, potentially improving mental health.12567
Who Is on the Research Team?
Randi M Schuster, PhD
Principal Investigator
Massachusetts General Hospital
Are You a Good Fit for This Trial?
This trial is for adolescents aged 12-18 who experience depression or suicidal thoughts and use cannabis. It aims to understand how cannabis affects their mood and risk of suicide, with the goal of creating better interventions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline
Participants complete a 2-week baseline phase involving real-time, ambulatory smartphone monitoring while using cannabis as usual
Randomized Treatment
Participants are randomized to either 8 weeks of cannabis abstinence with contingency management or non-contingent monitoring with no abstinence requirement
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Contingency management for cannabis abstinence
Contingency management for cannabis abstinence is already approved in United States, European Union, Canada for the following indications:
- Substance Abuse Treatment
- Cannabis Use Disorder
- Substance Abuse Treatment
- Cannabis Use Disorder
- Substance Abuse Treatment
- Cannabis Use Disorder
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborator